Kelly M Chin Selected Research

Epoprostenol Receptors

1/2022	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
1/2021	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
1/2021	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
1/2019	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
1/2016	Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
12/2015	Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kelly M Chin Research Topics

Disease

23	Pulmonary Arterial Hypertension 09/2022 - 12/2006
6	Disease Progression 01/2022 - 01/2019
3	Pulmonary Hypertension 03/2021 - 12/2006
2	Headache (Headaches) 10/2021 - 12/2015
2	Diarrhea 10/2021 - 12/2015
2	Nausea 10/2021 - 12/2015
2	Congenital Heart Defects (Congenital Heart Defect) 01/2019 - 01/2009
1	Pericardial Effusion 09/2022
1	Lung Diseases (Lung Disease) 03/2021
1	Right Ventricular Dysfunction 03/2021
1	Pain (Aches) 12/2015
1	Hypertension (High Blood Pressure) 01/2013
1	Thrombocytopenia (Thrombopenia) 01/2009
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2009
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 10/2008
1	Idiopathic Interstitial Pneumonias 10/2008
1	Familial Primary Pulmonary Hypertension 12/2006

Drug/Important Bio-Agent (IBA)

12	selexipagIBA 01/2022 - 12/2015
9	Epoprostenol (Prostacyclin)FDA LinkGeneric 09/2022 - 09/2007
6	Epoprostenol ReceptorsIBA 01/2022 - 12/2015
3	macitentanIBA 10/2021 - 01/2018
2	ProstaglandinsIBA 03/2021 - 01/2018
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2019 - 09/2007
2	Pharmaceutical PreparationsIBA 02/2014 - 12/2006
2	FenfluramineIBA 01/2009 - 12/2006
1	Tadalafil (Cialis)FDA Link 10/2021
1	Fluoxetine (Prozac)FDA LinkGeneric 10/2020
1	pro-brain natriuretic peptide (1-76)IBA 01/2019
1	treprostinil FDA Link 01/2019
1	Endothelin Receptor AntagonistsIBA 12/2015
1	Phosphodiesterase 5 InhibitorsIBA 12/2015
1	Mannitol (Osmitrol)FDA LinkGeneric 02/2014
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 02/2014
1	Arginine (L-Arginine)FDA Link 02/2014
1	Excipients (Suspending Agents)IBA 02/2014
1	Troponin IIBA 06/2013
1	Natriuretic PeptidesIBA 01/2013
1	Endothelin A ReceptorIBA 02/2010
1	ambrisentan FDA Link 02/2010
1	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2008
1	DNA (Deoxyribonucleic Acid)IBA 10/2008
1	telomerase RNA (bTR)IBA 10/2008
1	Bosentan (Tracleer)FDA Link 06/2008
1	Cocaine (Cocaine HCl)IBA 12/2006
1	Amphetamine (Amfetamine)FDA LinkGeneric 12/2006
1	Methamphetamine (Desoxyn)FDA LinkGeneric 12/2006

Therapy/Procedure

11	Therapeutics 09/2022 - 09/2007
1	Aftercare (After-Treatment) 06/2008